Literature DB >> 30456672

Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients.

Pompiliu Piso1, Sebastian D Nedelcut2, Beate Rau3, Alfred Königsrainer4, Gabriel Glockzin5,6, Michael A Ströhlein7, Rüdiger Hörbelt8, Jörg Pelz9.   

Abstract

BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are performed for well-selected patients with peritoneal surface malignancies. This combined treatment is potentially associated with an increased rate of complications.
OBJECTIVE: The aim of this paper was to analyze the morbidity and mortality of CRS and HIPEC in the German national registry.
METHODS: We present a retrospective analysis of 2149 consecutive patients from 52 hospitals. The data were prospectively documented in the DGAV StuDoQ Registry between February 2011 and December 2016.
RESULTS: Almost two-thirds of all patients had a colorectal malignancy; therefore, the most frequently performed resections were colectomies (54%) and rectal resections (30%). Only 36.2% of all patients had no anastomosis, and fewer than 20% of all patients were older than 70 years of age (16.4%). Enteric fistula and anastomotic leaks occurred in 10.5% of all cases. The reoperation rate was 14.6% (95% confidence interval [CI] 11.51-18.1). Major grade 3 and 4 complications (Clavien-Dindo classification) occurred in 19.3% of all patients, half of which were due to surgical complications. The overall 30-day postoperative hospital mortality was 2.3% (95% CI 1.02-3.85). Multivariate analysis showed an increased risk for morbidity associated with pancreatic resections (odds ratio [OR] 2.4), rectal resection (OR 1.5), or at least one anastomosis (OR 1.35), and mortality with reoperation (OR 8.7) or age > 70 years (OR 3.35).
CONCLUSIONS: CRS and HIPEC are associated with acceptable morbidity and low mortality. These results show that CRS and HIPEC can be safely performed nationwide when close mentoring by experienced centers is provided.

Entities:  

Mesh:

Year:  2018        PMID: 30456672     DOI: 10.1245/s10434-018-6992-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

Review 1.  [Hyperthermic intraperitoneal chemotherapy].

Authors:  H Leebmann; P Piso
Journal:  Chirurg       Date:  2019-07       Impact factor: 0.955

2.  Extraperitoneal Approach During Peritonectomy in the Right Upper Quadrant for Peritoneal Metastases from Ovarian Malignancies.

Authors:  Miklos Acs; Hubert Leebmann; Sebastian Häusler; Philipp Harter; Pompiliu Piso
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

3.  Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.

Authors:  Alberto Di Leo; Arianna Corvasce; Jacopo Weindelmayer; Elena Jane Mason; Francesco Casella; Giovanni de Manzoni
Journal:  Updates Surg       Date:  2020-05-14

4.  Liver metastasectomy-cytoreductive surgery- hyperthermic intraperitoneal chemotherapy and ileal pouch-anal anastomosis: A case report.

Authors:  Leonidas Chardalias; Antonios Gklavas; Ira Sotirova; Erasmia Vlachou; John Kontis; Ioannis Papaconstantinou
Journal:  Int J Surg Case Rep       Date:  2020-06-13

5.  Cytoreductive surgery and HIPEC in a 14 years old patient with peritoneal recurrence of adenocarcinoma of the right colon.

Authors:  Lorena Sorrentino; Francesco Serra; Francesca Cabry; Stefano De Julis; Elisa Barbieri; Massimo Girardis; Pier Luca Ceccarelli; Roberta Gelmini
Journal:  Int J Surg Case Rep       Date:  2019-03-21

6.  Thirty-three long-term survivors after cytoreductive surgery in patients with peritoneal metastases from colorectal cancer: a retrospective descriptive study.

Authors:  Yasuyuki Kamada; Koya Hida; Haruaki Ishibashi; Shouzou Sako; Akiyoshi Mizumoto; Masumi Ichinose; Naveen Padmanabhan; Shinya Yoshida; Yutaka Yonemura
Journal:  World J Surg Oncol       Date:  2021-01-28       Impact factor: 2.754

7.  Impact of insurance status on overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).

Authors:  Ravi J Chokshi; Jin K Kim; Jimmy Patel; Joseph B Oliver; Omar Mahmoud
Journal:  Pleura Peritoneum       Date:  2020-08-04

8.  Feasibility and outcomes of cytoreductive surgery and HIPEC for peritoneal surface malignancies in low- and middle-income countries: a single-center experience of 232 cases.

Authors:  Suryanarayana Deo; Mukurdipi Ray; Babul Bansal; Sandeep Bhoriwal; Sushma Bhatnagar; Rakesh Garg; Nishkarsh Gupta; Atul Sharma; Lalit Kumar; Sanjay Thulkar; Ekta Dhamija; Sandeep Mathur; Prasenjit Das
Journal:  World J Surg Oncol       Date:  2021-06-05       Impact factor: 2.754

9.  Combined modality therapy including cytoreductive surgery and heated intraperitoneal chemotherapy for synchronous low volume peritoneal carcinomatosis from adenocarcinoma of the tail of pancreas in a BRCA-2 carrier resulting in long-term disease-free survival: A case report.

Authors:  Richard A Hoefer; Chukwuemeka Obiora; Basem Azab; Elizabeth A Harden; John F Kessler
Journal:  Int J Surg Case Rep       Date:  2021-05-29

10.  Safety of coloanal/ileoanal anastomosis during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: results of 20 consecutive patients.

Authors:  Ozgul Duzgun; Murat Kalin
Journal:  J Int Med Res       Date:  2019-09-10       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.